Anti-CD86 [BU63] mAb

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-CD86 [BU63] mAb
• Alternate name: B7.2
• Research fields: Cell biology;Immunology;Stem cell biology
• Clone: BU63
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Strain: Balb/c
• Reactivity: Human
• Host: Mouse
• Application: FACS ; IHC ; IF ; IP ; WB
• Description: Monoclonal antibody directed against CD86 glycoprotein, without impacting on CTLA-4 activity. It aids the investigation of the adaptive immune response system.
• Immunogen: ARH 77 (B-lymphoblastoid cell line)
• Immunogen uniprot id: P42081
• Isotype: IgG1
• Myeloma used: P3/NS1/1-Ag4.1

Target Details

• Target: CD86
• Target background: CD86 is a 70 kDa type I transmembrane glycoprotein belonging to the immunoglobulin superfamily of cell surface receptors. CD86 was established during the 5th International Leukocyte Differentiation Antigen Workshop. CD86 is expressed on resting monocytes and dendritic cells, activated T and Natural Killer cells. CD86 rapidly induced on the surface of activated B-cells and is the ligand for two different proteins on the T cell surface: CD28, for autoregulation and intercellular association, and CTLA-4, for attenuation of regulation and cellular disassociation. CD86 works in tandem with CD80 to prime T cells in the primary immune response. CD86 is also expressed by malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkin's disease. Anti-CD86 BU63, alongside another monoclonal antibody, helped define CD86 single-chain cell-surface protein expressed by blood monocytes and activated B cells. This antibody does not block CTLA-4 binding to B7-2/B70, but induces a conformational change in CD86 which increases the binding affinity of soluble CTLA-4.

Applications

• Application: FACS ; IHC ; IF ; IP ; WB

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
• Shipping conditions: Shipping at 4° C

References

• Santos et al. 2019. Immunology. 157(4):296-303. PMID: 31162836.
• Jeffery et al. 2015. PLoS One. 10(7):e0131539. PMID: 26134669.
• Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function.
• Means et al. 2007. J Virol. 81(12):6573-83. PMID: 17409151.
• The Kaposi's sarcoma-associated herpesvirus K5 E3 ubiquitin ligase modulates targets by multiple molecular mechanisms.
• Gigure et al. 2004. J Virol. 78(12):6222-32. PMID: 15163715.
• Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle.
• O'Sullivan et al. 2002. J Immunol. 168(11):5491-8. PMID: 12023343.
• CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-kappaB.
• Latour et al. 2001. J Immunol. 167(5):2547-54. PMID: 11509594.
• Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation.
• Mauri et al. 1995. J Immunol. 155(1):118-27. PMID: 7541409.
• Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
• Schlossman SF et al. 1995. Leucocyte Typing V Oxford University Press.
• Caux et al. 1994. J Exp Med. 180(5):1841-7. PMID: 7525840.
• B70/B7-2 is identical to CD86 and is the major Fn ligand for CD28 expressed on human dendritic cells.
• Engel et al. 1994. Blood. 84(5):1402-7. PMID: 7520767.
• The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen.
• Nozawa et al. 1993. J Pathol. 169(3):309-15. PMID: 8492223.
• A novel monoclonal antibody (FUN-1) identifies an activation antigen in cells of the B-cell lineage and Reed-Sternberg cells.